Kim Young Eun, Sicuri Elisa, Tediosi Fabrizio
Swiss Tropical and Public Health Institute, Basel, Switzerland; University of Basel, Basel, Switzerland.
ISGlobal, Barcelona Centre for International Health Research (CRESIB), Hospital Clínic - Universitat de Barcelona, Barcelona, Spain.
PLoS Negl Trop Dis. 2015 Sep 11;9(9):e0004056. doi: 10.1371/journal.pntd.0004056. eCollection 2015.
Onchocerciasis (river blindness) is a parasitic disease transmitted by blackflies. Symptoms include severe itching, skin lesions, and vision impairment including blindness. More than 99% of all cases are concentrated in sub-Saharan Africa. Fortunately, vector control and community-directed treatment with ivermectin have significantly decreased morbidity, and the treatment goal is shifting from control to elimination in Africa.
We estimated financial resources and societal opportunity costs associated with scaling up community-directed treatment with ivermectin and implementing surveillance and response systems in endemic African regions for alternative treatment goals--control, elimination, and eradication. We used a micro-costing approach that allows adjustment for time-variant resource utilization and for the heterogeneity in the demographic, epidemiological, and political situation.
The elimination and eradication scenarios, which include scaling up treatments to hypo-endemic and operationally challenging areas at the latest by 2021 and implementing intensive surveillance, would allow savings of $1.5 billion and $1.6 billion over 2013-2045 as compared to the control scenario. Although the elimination and eradication scenarios would require higher surveillance costs ($215 million and $242 million) than the control scenario ($47 million), intensive surveillance would enable treatments to be safely stopped earlier, thereby saving unnecessary costs for prolonged treatments as in the control scenario lacking such surveillance and response systems.
The elimination and eradication of onchocerciasis are predicted to allow substantial cost-savings in the long run. To realize cost-savings, policymakers should keep empowering community volunteers, and pharmaceutical companies would need to continue drug donation. To sustain high surveillance costs required for elimination and eradication, endemic countries would need to enhance their domestic funding capacity. Societal and political will would be critical to sustaining all of these efforts in the long term.
盘尾丝虫病(河盲症)是一种由蚋传播的寄生虫病。症状包括严重瘙痒、皮肤病变以及视力损害,甚至失明。所有病例中超过99%集中在撒哈拉以南非洲地区。幸运的是,病媒控制和伊维菌素社区导向治疗已显著降低发病率,在非洲,治疗目标正从控制转向消除。
我们估计了与扩大伊维菌素社区导向治疗以及在非洲流行地区实施监测和应对系统相关的财政资源和社会机会成本,以实现替代治疗目标——控制、消除和根除。我们采用微观成本核算方法,该方法允许根据随时间变化的资源利用情况以及人口、流行病学和政治状况的异质性进行调整。
消除和根除方案,包括最迟在2021年将治疗扩大到低流行和操作具有挑战性的地区并实施强化监测,与控制方案相比,在2013 - 2045年期间将节省15亿美元和16亿美元。尽管消除和根除方案比控制方案(4700万美元)需要更高的监测成本(2.15亿美元和2.42亿美元),但强化监测将使治疗能够更早安全停止,从而节省如控制方案中因缺乏此类监测和应对系统而进行长期治疗的不必要成本。
预计消除和根除盘尾丝虫病从长远来看将大幅节省成本。为实现成本节约,政策制定者应继续赋予社区志愿者权力,制药公司需要继续捐赠药物。为维持消除和根除所需的高昂监测成本,流行国家需要提高其国内筹资能力。社会和政治意愿对于长期维持所有这些努力至关重要。